The U.S. Food and Drug Administration is working at 'lightning speed' to review data on Gilead Sciences Inc's experimental antiviral drug remdesivir in treating COVID-19 disease, the head of the agency told Bloomberg in an interview.
Gilead Sciences Inc pharmaceutical company is seen after they announced a Phase 3 Trial of the investigational antiviral drug Remdesivir in patients with severe coronavirus disease , during the outbreak of the coronavirus disease , in Oceanside, California, U.S., April 29, 2020. REUTERS/Mike Blake
- The U.S. Food and Drug Administration is working at “lightning speed” to review data on Gilead Sciences Inc’s experimental antiviral drug remdesivir in treating COVID-19 disease, the head of the agency told Bloomberg in an interview. “We’re working with the company to emphasize the necessity of speed while at the same time to understand the data,” FDA Commissioner Stephen Hahn said.
Meanwhile, the FDA in an email statement to Reuters, reiterated it was in talks with Gilead about making the drug available to patients as quickly as possible. Anthony Fauci, the top U.S. infectious disease official, had said on Wednesday remdesivir will become the standard of care for COVID-19 after early clinical trial results showed it helped patients recover more quickly from the illness caused by the coronavirus.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Study Shows Shorter Course of Gilead Drug as Effective Against Covid-19Gilead Sciences said its phase 3 study for the antiviral remdesivir demonstrated that patients with severe Covid-19 taking the drug over a five-day treatment had similar improvement compared with those taking the 10-day course.
Read more »
Gilead Sciences says there are 'positive data' from a study on possible Covid-19 treatment remdesivirThere's 'positive data' emerging from a study on possible Covid-19 treatment remdesivir, the maker of the investigational drug says
Read more »
Gilead says remdesivir shows improvement in COVID-19 patients when used earlyGilead Sciences Inc on Wednesday said its experimental antiviral drug remdesivir helped improve outcomes for patients with COVID-19, and provided data suggesting it worked better when given earlier in the course of infection.
Read more »
Opinion | An Experimental Ultraviolet Light Treatment for Covid-19 Takes Political HeatFrom WSJopinion: Social-media companies are censoring information about the Covid-19 treatment my company is developing after Trump mentioned it, writes josh_disbrow
Read more »
Study: Remdesivir appears to speed recovery times in hospitalized COVID-19 patientsEarly results released from a federal study found patients who received remdesivir had a 31% faster recovery time than those who received a placebo.
Read more »
Coronavirus updates: 1 million COVID-19 cases in USA nurse received rousing applause from her neighbors, as they gathered to cheer for her on her way to work in Bethesda, Maryland.
Read more »